Pfizer Canada announces Health Canada approval of Abrysvo for adults 18+

21 October 2025 - With the approval of Arbysvo for adults aged 18+, there is now a way to help ...

Read more →

Alzinova receives fast track designation from US FDA for ALZ-101 in Alzheimer’s disease

4 October 2025 - Alzinova today announces that the US FDA has granted fast track designation for the company’s vaccine candidate ...

Read more →

Moderna produces its first Canadian mRNA vaccines in its new state of the art Quebec facility

19 September 2025 - Today, the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for ...

Read more →

Moderna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2

27 August 2025 - Moderna today announced that the US FDA has approved the supplemental biologics license applications for the ...

Read more →

Pfizer and BioNTech’s Comirnaty receives US FDA approval for adults 65 and older and individuals ages 5 through 64 at increased risk for severe COVID-19

27 August 2025 - The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sub-lineage LP.8.1, in line with FDA guidance to more ...

Read more →

Moderna receives Health Canada approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1

22 August 2025 - All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone. ...

Read more →

Pfizer Canada and BioNTech receive Health Canada approval of LP.8.1 variant adapted COVID-19 vaccine

18 August 2025 - LP.8.1 variant adapted COVID-19 vaccine Cominaty is now authorised in Canada for individuals 6 months of age ...

Read more →

Valneva’s chikungunya vaccine Ixchiq now authorised in Canada for individuals aged 12 and plder

18 August 2025 - Valneva today announced that Health Canada has granted marketing authorisation for its single dose vaccine, Ixchiq, ...

Read more →

EMA CHMP adopts positive opinion recommending authorisation of Moderna's COVID-19 mRNA vaccine targeting the SARS-CoV-2 variant LP.8.1

25 July 2025 - Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European ...

Read more →

Pfizer and BioNTech receive positive CHMP opinion for LP.8.1 adapted COVID-19 vaccine in the European Union

25 July 2025 - Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sub-lineages ...

Read more →

Bavarian Nordic receives acceptance from Health Canada for review of the new drug submission for its chikungunya vaccine

22 July 2025 -  Bavarian Nordic announced today that Health Canada has accepted for review the Company’s application for licensure ...

Read more →

US FDA approves GSK’s Shingrix in a pre-filled syringe presentation

17 July 2025 - Pre-filled syringe presentation offers a convenient administration option to health care professionals. ...

Read more →

US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk

14 July 2025 - FDA decision anticipated H1, 2026 ...

Read more →

Moderna receives full US FDA approval for COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years at increased risk for COVID-19 disease

10 July 2025 - Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 ...

Read more →

GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the EMA to expand use in adults 18 years and older

13 June 2025 - Regulatory decision anticipated H1, 2026. ...

Read more →